Neuphoria Therapeutics Inc. (NEUP) intrinsic value & 10-year financials
Neuphoria Therapeutics Inc. (NEUP) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue reached to $15.6M, with an average return on invested capital of -153.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.30
- Market cap
- $5.4M
- Revenue (FY2025)
- $15.6M
- ROIC (10-yr avg)
- -153.8%
- Free cash flow (FY2025)
- —
NEUP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $15.6M | -$369.6K | -$0.23 | — | -7.2% | -11.3% |
| FY2024 | — | -$15.5M | -$0.01 | — | — | -234.9% |
| FY2023 | — | -$21.4M | -$0.02 | — | — | -215.2% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Neuphoria Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Neuphoria Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -5.3% ROIC.
Neuphoria Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Neuphoria Therapeutics Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.